.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,829,017

« Back to Dashboard

Claims for Patent: 8,829,017

Title:Methods of treating traveler's diarrhea and hepatic encephalopathy
Abstract: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC)
Assignee: Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:13/076,967
Patent Claims: 1. A method of treating a patient having hepatic encephalopathy (HE) comprising: identifying a subject having Travelers' Diarrhea (TD) that also has hepatic insufficiency; determining if the subject's Child-Pugh score is Child-Pugh Class C or if the subject's model end stage liver disease (MELD) score is 25 or greater; and administering between 1000 and 1200 mg of rifaximin daily and cautiously to the subject if the subject's Child-Pugh score is Child-Pugh Class C or if the subject's MELD score is 25 or greater.

2. The method of claim 1, wherein the hepatic insufficiency is hepatic encephalopathy.

3. The method of claim 1, wherein the subject is treated for 12 to 72 hours.

4. The method of claim 1, wherein the subject is administered 1100 mg of rifaximin daily or 550 mg of rifaximin BID.

5. The method of claim 1, further comprising testing the subject for hepatic insufficiency.

6. The method of claim 1, wherein the TD is caused by bacterial, virus, or protozoan infection.

7. The method of claim 1, wherein the TD is caused by E. coli.

8. The method of claim 7, wherein the E. coli is enterotoxigenic E. coli.

9. The method of claim 1, wherein the subject is a human.

10. The method of claim 1, wherein systemic exposure of rifaximin is markedly elevated in patients with hepatic impairment compared to healthy subjects.

11. The method of claim 1, wherein the rifaximin comprises tablets for oral administration comprising one or more of colloidal silicon dioxide, disodium edetate, glycerol palmitostearate, hypromellose, microcrystalline cellulose, propylene glycol, red iron oxide, sodium starch glycolate, talc, or titanium dioxide.

12. The method of claim 1, wherein the duration of diarrhea was significantly shorter in a subject treated with rifaximin compared to an untreated subject.

13. The method of claim 1, wherein the clearance rate of rifaximin is decreased in a population of subjects with hepatic insufficiency as compared to population of subjects without hepatic insufficiency.

14. The method of claim 1, wherein the elimination rate of rifaximin is decreased in subjects with hepatic insufficiency as compared to subjects without hepatic insufficiency.

15. The method of claim 1, wherein the systemic exposure to rifaximin is increased in a population of subjects with hepatic insufficiency as compared to population of subjects without hepatic insufficiency.

16. The method of claim 1, wherein the serum level of rifaximin is increased in a population of subjects with hepatic insufficiency as compared to population of subjects without hepatic insufficiency.

17. A method of treating a patient suffering from hepatic encephalopathy (HE) comprising: identifying a subject having Traveler's Diarrhea (TD) that also has HE; determining the severity of the subject's HE; and administering between 1000 and 1200 mg of rifaximin daily and cautiously to the subject if the HE is severe.

18. The method of claim 17, wherein the subject is administered 1100 mg of rifaximin.

19. The method of claim 18, wherein the subject is administered 550 mg of rifaximin BID.

20. The method of claim 17, wherein the subject is a human.

21. The method of claim 17, wherein the rifaximin comprises tablets for oral administration comprising one or more of colloidal silicon dioxide, disodium edetate, glycerol palmitostearate, hypromellose, microcrystalline cellulose, propylene glycol, red iron oxide, sodium starch glycolate, talc, or titanium dioxide.

22. The method of claim 17, further comprising determining if the subject's Child-Pugh score is Child-Pugh Class C.

23. The method of claim 17, further comprising determining if the subject's model end stage liver disease (MELD) score is 25 or greater.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc